Summit Therapeutics (NASDAQ:SMMT - Get Free Report) was downgraded by investment analysts at Sanford C. Bernstein from a "market perform" rating to an "underperform" rating in a research note issued to investors on Wednesday, MarketBeat reports. They presently have a $8.30 price target on the stock, down from their prior price target of $11.90. Sanford C. Bernstein's target price suggests a potential downside of 22.21% from the stock's current price.
Several other brokerages have also commented on SMMT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. The Goldman Sachs Group set a $41.00 price objective on Summit Therapeutics and gave the stock a "buy" rating in a research report on Tuesday, September 29th. Leerink Partners upgraded shares of Summit Therapeutics from an "underperform" rating to a "market perform" rating and boosted their price objective for the company from $12.00 to $13.00 in a report on Wednesday, August 12th. Barclays reduced their price objective on shares of Summit Therapeutics from $20.00 to $18.00 and set an "equal weight" rating on the stock in a report on Monday. Finally, UBS Group reaffirmed a "neutral" rating on shares of Summit Therapeutics in a research report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $28.10.
Read Our Latest Stock Report on Summit Therapeutics
Summit Therapeutics Stock Down 9.7%
SMMT stock opened at $10.67 on Wednesday. The firm's 50 day moving average price is $16.16 and its 200-day moving average price is $16.09. Summit Therapeutics has a one year low of $10.53 and a one year high of $29.23.
Institutional Trading of Summit Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Summit Therapeutics during the 2nd quarter worth approximately $138,838,000. Bellevue Group AG boosted its position in Summit Therapeutics by 13,733.9% in the 3rd quarter. Bellevue Group AG now owns 2,113,681 shares of the company's stock valued at $35,742,000 after buying an additional 2,098,402 shares during the period. Candriam S.C.A. boosted its position in Summit Therapeutics by 212.3% in the 3rd quarter. Candriam S.C.A. now owns 1,662,969 shares of the company's stock valued at $28,224,000 after buying an additional 1,130,537 shares during the period. Bank of America Corp DE purchased a new position in Summit Therapeutics in the 2nd quarter valued at approximately $12,603,000. Finally, The Manufacturers Life Insurance Company boosted its position in Summit Therapeutics by 34.4% in the 1st quarter. The Manufacturers Life Insurance Company now owns 592,810 shares of the company's stock valued at $11,240,000 after buying an additional 151,857 shares during the period. Hedge funds and other institutional investors own 4.61% of the company's stock.
Summit Therapeutics Company Profile
(
Get Free Report)
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit's licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Summit Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.
While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.